Severity
Moderate
FDA Drug recall · Reported January 13, 2021
Lack of assurance of sterility: The results of sterility tests of seven batches of product were out of specification. Five of these batches tested positive for Ralstonia pickettii…
Merck Sharp & Dohme recalled Zerbaxa (ceftolozane and tazobactam) 1.5g per vial for injection, Single-Dose vial, Rx on… — a moderate-severity action.
Zerbaxa (ceftolozane and tazobactam) 1.5g per vial for injection, Single-Dose vial, Rx on… was recalled by Merck Sharp & Dohme in January 13, 2021. Reason: Lack of assurance of sterility: The results of sterility tests of seven batches of product were out of specif…. Check the official notice for the remedy. Verify recall #D-0176-2021 with the FDA Drug before acting.
The recall
Merck Sharp & Dohme issued this moderate-severity FDA Drug recall — Lack of assurance of sterility: The results of sterility tests of seven batches of product were out of specif….
Sourced from official FDA Drug enforcement records. Verify recall #D-0176-2021 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0176-2021) was formally reported on January 13, 2021, with the manufacturer initiating the action on December 21, 2020. It is classified under Moderate severity (Class II), with a current status of Terminated. Merck Sharp & Dohme is listed as the recalling firm, operating out of Rahway, NJ. Federal records list the affected scope as 106,503 vials.
The documented reason for this recall is: Lack of assurance of sterility: The results of sterility tests of seven batches of product were out of specification. Five of these batches tested positive for Ralstonia pickettii and two batches produced turbid results… Distribution data in the federal record shows the product reached: U.S.A. Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls — clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category — 25,414 food recalls on record
Of 100,165 recalls in the database, 23,668 are high severity, 72,097 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger — we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
106,503 vials
Related Recalls
6
0 from same agency
Zerbaxa (ceftolozane and tazobactam) 1.5g per vial for injection, Single-Dose vial, Rx only, Manuf. for: Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc., NDC 67919-030-01
Lack of assurance of sterility: The results of sterility tests of seven batches of product were out of specification. Five of these batches tested positive for Ralstonia pickettii and two batches produced turbid results that could not be further identified. While all product distributed to the market has met the registered specifications for release, including for sterility, it was manufactured on the same equipment as the affected batches.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0176-2021 |
| Date reported | January 13, 2021 |
| Date initiated | December 21, 2020 |
| Recalling firm | Merck Sharp & Dohme |
| Firm location | Rahway, NJ |
| Affected scope | 106,503 vials |
| Distribution | U.S.A. Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Keep tracking product safety across the federal recall archive.
Recall Checker
Search the full archive by product name, brand, or recall number across every agency.
Check a product →
FDA Drug recalls
Every recall issued by FDA Drug, newest first.
Browse the feed →
RecallRadar
Live feed of the latest recalls across the FDA, CPSC and NHTSA — filter by agency and severity.
View the live feed →
Rankings
The largest recalls by units affected and the most-recalled product categories.
See the rankings →
Browse by category
Find recalls by product type to spot recurring defect patterns.
All categories →
What to do next
A step-by-step guide to refunds, repairs, and returns after a recall.
Read the guide →
Other recalls in the same product category — useful for spotting patterns across the same defect class or manufacturer.
Legacy Bakehouse LLC · 2026-06-03
Honeyville, Inc · 2026-06-03
Legacy Bakehouse LLC · 2026-06-03
Legacy Bakehouse LLC · 2026-06-03
Wawa Beverage Company · 2026-06-03
Compare this recall with Butter Parsley Bagel Crisps, Item Number 18490, Net Weight:… →
Source: FDA, CPSC, and NHTSA federal recall databases. This recall: FDA Drug, reported January 13, 2021.
Recall information is sourced from official federal agency databases. Always verify recall details with the issuing agency for the most current status. This information is for research and awareness purposes only.
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records — no number is typed in by an editor. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of June 2026.